Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 01:16PM ET
1.43
Dollar change
+0.03
Percentage change
2.14
%
Index- P/E- EPS (ttm)-4.67 Insider Own21.45% Shs Outstand4.48M Perf Week-2.72%
Market Cap6.41M Forward P/E- EPS next Y- Insider Trans-0.36% Shs Float3.52M Perf Month0.70%
Income-10.15M PEG- EPS next Q- Inst Own1.39% Short Float1.66% Perf Quarter-74.00%
Sales0.04M P/S160.16 EPS this Y- Inst Trans28.33% Short Ratio0.68 Perf Half Y-50.46%
Book/sh1.91 P/B0.75 EPS next Y- ROA-81.33% Short Interest0.06M Perf Year-51.54%
Cash/sh1.29 P/C1.11 EPS next 5Y- ROE-93.21% 52W Range1.26 - 7.74 Perf YTD-74.58%
Dividend Est.- P/FCF- EPS past 5Y38.67% ROI-156.16% 52W High-81.52% Beta0.31
Dividend TTM- Quick Ratio5.57 Sales past 5Y-25.00% Gross Margin-7.47% 52W Low13.49% ATR (14)0.17
Dividend Ex-Date- Current Ratio5.57 EPS Y/Y TTM38.66% Oper. Margin-27641.21% RSI (14)30.42 Volatility5.46% 5.91%
Employees6 Debt/Eq0.08 Sales Y/Y TTM-82.77% Profit Margin-26946.19% Recom1.00 Target Price90.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q57.05% Payout- Rel Volume0.33 Prev Close1.40
Sales Surprise- EPS Surprise40.00% Sales Q/Q-91.32% Earnings- Avg Volume86.25K Price1.43
SMA20-0.31% SMA50-48.15% SMA200-59.24% Trades Volume17,280 Change2.14%
Mar-18-24 07:00AM
Mar-17-24 08:38AM
Mar-05-24 07:45AM
Mar-01-24 04:04PM
Feb-27-24 09:25PM
04:33PM Loading…
04:33PM
Feb-12-24 04:41PM
Feb-07-24 08:00AM
Feb-05-24 08:00AM
Jan-23-24 05:34PM
Jan-02-24 07:30AM
Nov-10-23 09:19AM
Nov-02-23 07:00AM
Oct-18-23 08:30AM
08:30AM
06:30AM Loading…
Oct-05-23 06:30AM
Sep-29-23 04:00PM
Aug-14-23 02:46PM
Aug-07-23 08:30AM
Jun-05-23 04:18PM
May-12-23 06:32PM
Mar-29-23 11:45AM
Mar-14-23 08:30AM
Mar-08-23 09:09AM
Mar-01-23 01:47PM
07:30AM
Feb-03-23 07:30AM
Jan-30-23 02:24PM
Dec-23-22 04:05PM
Dec-22-22 07:30AM
04:36PM Loading…
Dec-20-22 04:36PM
Dec-19-22 04:34PM
Oct-24-22 04:01PM
Sep-30-22 07:30AM
Aug-24-22 07:00AM
Jun-23-22 04:30PM
Jun-14-22 07:30AM
May-17-22 07:30AM
May-13-22 04:17PM
Apr-18-22 07:30AM
Apr-06-22 07:30AM
Mar-25-22 07:30AM
Mar-22-22 08:59AM
Mar-10-22 07:30AM
Mar-03-22 09:09AM
Feb-07-22 01:45PM
Jan-26-22 07:30AM
Jan-14-22 05:38PM
Jan-04-22 12:02PM
Dec-20-21 12:08PM
08:00AM
Dec-09-21 08:00AM
Dec-08-21 08:00AM
Dec-01-21 08:00AM
Nov-23-21 08:30AM
Oct-04-21 07:30AM
Sep-15-21 11:01AM
07:30AM
Aug-31-21 09:15AM
Aug-30-21 10:06AM
07:30AM
Aug-24-21 07:30AM
Jul-27-21 07:00AM
Jul-12-21 10:10AM
Jul-01-21 07:00AM
May-18-21 07:30AM
May-03-21 07:30AM
Apr-09-21 10:50AM
Mar-09-21 12:09PM
07:00AM
Mar-08-21 07:30AM
Feb-12-21 08:00AM
Feb-02-21 08:00AM
Jan-14-21 07:00AM
Jan-07-21 07:00AM
Dec-29-20 04:00PM
Dec-24-20 08:30AM
Dec-02-20 09:37AM
Nov-24-20 11:37AM
Nov-20-20 08:30AM
Nov-19-20 05:14PM
Oct-06-20 07:30AM
Sep-28-20 07:30AM
Sep-11-20 07:30AM
Sep-03-20 09:47AM
Aug-20-20 08:30AM
Jul-22-20 07:30AM
Jul-10-20 07:30AM
Jun-04-20 08:00AM
Jun-03-20 09:00AM
May-19-20 08:01AM
May-08-20 05:45AM
May-04-20 06:15AM
06:00AM
Apr-15-20 06:30AM
Mar-09-20 10:50AM
Dec-10-19 11:16AM
Dec-03-19 08:30AM
Dec-02-19 09:45AM
08:30AM
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Telling FredDirectorNov 30 '23Sale3.573,50012,48838,345Dec 01 05:23 PM